BridgeBio Pharma
BBIO
392 hedge funds and large institutions have $9.62B invested in BridgeBio Pharma in 2025 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 148 increasing their positions, 134 reducing their positions, and 38 closing their positions.
491% more call options, than puts
Call options by funds: $613M | Put options by funds: $104M
97% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 38
18% more capital invested
Capital invested by funds: $8.15B → $9.62B (+$1.46B)
10% more repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 134
9% more funds holding
Funds holding: 359 → 392 (+33)
2.59% less ownership
Funds ownership: 99.44% → 96.85% (-2.6%)
18% less funds holding in top 10
Funds holding in top 10: 17 → 14 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$60.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$55M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$51.3M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$47.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$126M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$100M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$73.5M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$32.9M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$32.1M |
BBIO Hedge Fund Activity: Q3 2025 in Review
392 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2025, worth a combined $9.62B — up 18% from $8.15B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new BBIO positions and 38 closed out — a net gain of 37 holders — while 148 added to existing stakes and 134 trimmed.
The largest buyer was Hood River Capital Management, opening a new position worth an estimated $60.7M. The largest seller was Viking Global Investors, cutting an estimated $126M.
- 392 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2025, up from 359 in Q2 2025.
- Funds reported $9.62B of BridgeBio Pharma stock for Q3 2025, up 18% quarter-over-quarter.
- 75 funds opened new BridgeBio Pharma positions in Q3 2025 and 38 closed out, a net change of +37 holders.
- The largest BridgeBio Pharma buyer in Q3 2025 was Hood River Capital Management, an estimated $60.7M added.
- The largest BridgeBio Pharma seller in Q3 2025 was Viking Global Investors, an estimated $126M sold.
Based on aggregated 13F filings for Q3 2025.